Virinchi Limited has scheduled its 37th Annual General Meeting (AGM) for September 30, 2026. The Board of Directors also approved the Board Report and Corporate Governance Report for the financial year ended March 31, 2026.

The meeting will be conducted through Video Conferencing or Other Audio Visual Means (VC/OVAM). This follows a Board meeting held on August 22, 2026, which commenced at 6:30 pm and concluded at 7:00 pm.

Director Re-appointment

The Board re-appointed Mr. Satyanarayana Vedula as a director. He retires by rotation and is eligible for re-appointment.

Mr. Vedula is a qualified Chartered Accountant with over 23 years of experience at Tech Mahindra. His expertise spans sales, global delivery, and program management across BFSI and Health verticals. He holds certifications as a Certified Global Business Leader and Six Sigma Black Belt.

Regulatory Compliance

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026.

Shareholders of Virinchi Limited have approved the acquisition of its primary and secondary healthcare business division operating under the Bristlecone Hospitals brand. The transaction involves a slump sale from Virinchi Health Care Private Limited, identified as a material subsidiary of the company. This consolidation moves key healthcare assets into the parent entity’s direct control, streamlining operations for this significant segment of the group.

The resolution was passed through a postal ballot process that concluded on August 10, 2026. The voting exercise was conducted in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 108 and 109 of the Companies Act, 2013. CS Vinay Babu Gade served as the independent scrutinizer for the voting process, ensuring adherence to regulatory guidelines including relevant MCA circulars.

Voting Results Breakdown

The approval reflects strong shareholder confidence in the restructuring move. Out of 37,924 shareholders on the record date of July 3, 2026, participation was driven primarily by public non-institutional investors. Promoters and institutional investors did not cast votes in this ballot.

The total number of valid votes cast was 5,510,829. There were no invalid votes recorded during the e-voting period, which ran from July 12, 2026, to August 10, 2026. Central Depository Services (India) Limited (CDSL) facilitated the remote e-voting facility.

Transaction Details

The acquisition is structured as a slump sale, allowing for the transfer of the entire business division as a going concern rather than asset-by-asset. This approach typically simplifies the legal and operational transition of staff, contracts, and liabilities associated with the Bristlecone Hospitals brand. The promoters of Virinchi Limited are interested parties in this resolution, as noted in the filing disclosures.

What the Numbers Show

The high level of support—over 95%—from public non-institutional shareholders indicates broad alignment with the company’s strategy to consolidate its healthcare assets. Notably, the promoter group, holding 44,475,538 shares, abstained from voting. This abstention is common in related-party transactions where promoters may recuse themselves to ensure independent shareholder validation, thereby strengthening the governance credibility of the approval.